Cite
MLA Citation
Joanne M. Donovan et al.. “A Novel NF‐κB Inhibitor, Edasalonexent (CAT‐1004), in Development as a Disease‐Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects.” Journal of clinical pharmacology, vol. 57, 2017, pp. 627–639. http://access.bl.uk/ark:/81055/vdc_100045410882.0x000043